Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptors, Androgen”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02144051
What this trial is testing

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

Who this might be right for
Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
AstraZeneca 32
Testing effectiveness (Phase 2)Looking for participantsNCT07142551
What this trial is testing

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 60
Testing effectiveness (Phase 2)Looking for participantsNCT07226986
What this trial is testing

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Who this might be right for
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals 123
Testing effectiveness (Phase 2)Looking for participantsNCT05095207
What this trial is testing

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastasis
Icahn School of Medicine at Mount Sinai 42
Testing effectiveness (Phase 2)Looking for participantsNCT05404139
What this trial is testing

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

Who this might be right for
Metastatic Prostate Cancer
University Health Network, Toronto 352
Testing effectiveness (Phase 2)Active Not RecruitingNCT07047118
What this trial is testing

JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals 138
Not applicableStudy completedNCT00002924
What this trial is testing

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

Who this might be right for
Prostate Cancer
Alliance for Clinical Trials in Oncology 184
Not applicableStudy completedNCT01977313
What this trial is testing

Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women

Who this might be right for
LibidoReceptors, AndrogenPolymorphism, Genetic+1 more
Insel Gruppe AG, University Hospital Bern 45
Not applicableUnknownNCT05716152
What this trial is testing

Hormonal Associations in Male Patients With Psoriasis Vulgaris

Who this might be right for
Psoriasis Vulgaris
Sohag University 102
Testing effectiveness (Phase 2)Looking for participantsNCT07832292
What this trial is testing

JNJ-101556143 in Participants With Metastatic Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 100
Testing effectiveness (Phase 2)Ended earlyNCT01616758
What this trial is testing

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
GTx 22
Early research (Phase 1)Study completedNCT02672475
What this trial is testing

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+3 more
Vanderbilt-Ingram Cancer Center 29
Testing effectiveness (Phase 2)Study completedNCT02971761
What this trial is testing

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Who this might be right for
Androgen Receptor PositiveEstrogen Receptor NegativeHER2/Neu Negative+3 more
City of Hope Medical Center 18
Early research (Phase 1)UnknownNCT05673694
What this trial is testing

To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Changchun GeneScience Pharmaceutical Co., Ltd. 70
Testing effectiveness (Phase 2)Study completedNCT01393730
What this trial is testing

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Mary-Ellen Taplin, MD 40
Testing effectiveness (Phase 2)Ended earlyNCT00303615
What this trial is testing

Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Legacy Health System 5
Testing effectiveness (Phase 2)UnknownNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69
Testing effectiveness (Phase 2)Study completedNCT02689427
What this trial is testing

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Who this might be right for
Invasive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7+9 more
M.D. Anderson Cancer Center 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511
What this trial is testing

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 7
Testing effectiveness (Phase 2)Ended earlyNCT02348281
What this trial is testing

Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients

Who this might be right for
Breast Cancer
Fudan University 1
Next Page